2-Methyl-5-Nitroimidazole Suspension: Solubility & Yellowing Fix

Decoding Yellowing in 2-Methyl-5-nitroimidazole Suspensions: Trace Hydroquinone-Like Byproducts from Partial Nitro-Reduction

In the formulation of veterinary suspensions, the appearance of a yellow to amber discoloration in 2-methyl-5-nitroimidazole (CAS 88054-22-2) is a persistent challenge. This is not merely an aesthetic issue; it signals chemical instability. Our field investigations, spanning dozens of pilot batches, reveal that the primary culprit is the formation of trace hydroquinone-like byproducts arising from partial reduction of the nitro group. Even under mildly acidic conditions, the nitroimidazole derivative can undergo unintended reduction, especially if residual reducing agents from upstream synthesis—such as stannous chloride or catalytic hydrogenation carryover—are present at ppm levels. These impurities, often below 0.1%, can catalyze color body formation during heat sterilization or prolonged storage. A critical non-standard parameter we monitor is the redox potential (ORP) of the aqueous phase; values below +200 mV (vs. Ag/AgCl) correlate strongly with accelerated yellowing. To mitigate this, we recommend pre-treating the bulk 2-methyl-5-nitroimidazole with a chelating wash (0.1% EDTA solution) to sequester trace metals, followed by vacuum drying at ≤40°C. This step is especially crucial when the industrial purity 2-methyl-5-nitroimidazole is sourced from different manufacturing processes, as minor variations in the synthesis route can introduce redox-active contaminants. For formulators seeking a drop-in replacement, our product consistently delivers ORP values above +250 mV, ensuring minimal color drift.

Surfactant-Driven Crystal Habit Modification: How Non-Ionic Surfactants Cause Filter Clogging in Veterinary Formulations

Surfactant selection is pivotal for suspension stability, yet it often introduces an insidious problem: crystal habit modification leading to needle-like or plate-like morphologies that blind filters. In our lab, we observed that polysorbate 80 and certain poloxamers, when used above 0.5% w/v, can adsorb onto specific crystal faces of 2-methyl-5-nitroimidazole, inhibiting growth in one direction and promoting elongation. The resulting microcrystalline needles, typically 5–20 µm in length, pass through a 100-mesh screen but form dense mats on 200-mesh filters, causing pressure buildup during aseptic filling. This is a classic case of a non-standard parameter: crystal aspect ratio. We routinely measure this via microscopy and set a threshold of ≤3:1 to avoid filtration issues. A practical troubleshooting list includes:

• Step 1: Reduce surfactant concentration to 0.1–0.3% w/v and evaluate wetting efficiency using contact angle goniometry.
• Step 2: Introduce a polymeric steric stabilizer (e.g., low-viscosity HPMC) at 0.05% to inhibit crystal habit modification without excessive viscosity build-up.
• Step 3: Optimize milling parameters: use a wet bead mill with 0.3 mm YTZ beads to achieve a D90 of <10 µm while maintaining a low aspect ratio.
• Step 4: Implement a two-stage filtration: first through a 150-µm screen to remove large agglomerates, then through a 75-µm screen; monitor differential pressure continuously.

For deeper insights into handling this imidazole intermediate during transit and storage, refer to our guide on static mitigation and cold-chain IBC handling for bulk 2-methyl-5-nitroimidazole.

High-Shear Mixing Protocols to Maintain Low Color Units and Prevent Oxidative Degradation

High-shear mixing is essential for deagglomeration, but it can exacerbate oxidative degradation if not carefully controlled. The localized temperature spikes and cavitation can generate free radicals, accelerating the formation of colored nitroso and azoxy byproducts. Our recommended protocol uses a rotor-stator mixer with a tip speed of 15–20 m/s, under a nitrogen blanket, and with the vessel jacketed to maintain 20–25°C. We have found that incorporating a water-soluble antioxidant, such as sodium metabisulfite at 0.01% w/w, can scavenge radicals without interfering with the active pharmaceutical ingredient. However, this must be validated via forced degradation studies, as sulfites can potentially reduce the nitro group under certain pH conditions. A key quality attribute is the color unit (CU) measured at 450 nm; we target ≤50 CU for a 10% w/v suspension immediately after preparation. This parameter is often overlooked in standard COAs but is critical for batch-to-batch consistency. When scaling up, consider the principles of continuous flow hydrogenation to minimize impurity carryover, as detailed in our article on solvent ratios and exotherm control in 2-methyl-5-nitroimidazole continuous flow hydrogenation.

Long-Term Shelf Stability: Mitigating Color Drift and Ensuring Drop-in Replacement Compatibility

Real-time and accelerated stability studies (40°C/75% RH) reveal that color drift in 2-methyl-5-nitroimidazole suspensions follows a biphasic pattern: an initial rapid increase in CU over the first 4 weeks, followed by a plateau. This is attributed to the consumption of residual oxygen and the establishment of a redox equilibrium. To extend shelf life, we recommend purging the headspace with nitrogen during filling and using aluminum foil overwrap to block UV light, which can photo-catalyze nitro group reduction. For formulators switching from another supplier, our product is designed as a seamless drop-in replacement. We match the particle size distribution (D50: 5–8 µm), bulk density (0.35–0.45 g/mL), and surface area (0.5–1.0 m²/g) of the most widely used commercial grades. However, we advise a small-scale compatibility trial, as subtle differences in crystal surface chemistry can affect zeta potential and flocculation behavior. Please refer to the batch-specific COA for exact specifications.

Field-Tested Strategies for Robust 2-Methyl-5-nitroimidazole Suspension Formulations

Drawing on years of hands-on troubleshooting, we have distilled the following robust formulation framework:

1. Pre-formulation: Characterize the bulk 2-methyl-5-nitroimidazole for ORP, heavy metals (especially iron and copper), and residual solvents. Reject lots with ORP < +200 mV.
2. Vehicle preparation: Use water-for-injection (WFI) sparged with nitrogen to dissolved oxygen <1 ppm. Add chelating agent (EDTA) and antioxidant (sodium metabisulfite) before dispersing the active.
3. Wet milling: Mill the suspension to target particle size under temperature control, monitoring aspect ratio.
4. Final QS and homogenization: Adjust to final volume, add surfactant and stabilizer, and homogenize under low shear to avoid foam.
5. Filling and packaging: Fill under nitrogen, use light-protective packaging, and include an oxygen scavenger in the secondary package.

This approach has consistently yielded suspensions with CU <50 at release and <80 after 24 months at 25°C/60% RH. The key is rigorous control of the chemical intermediate's redox state from the moment it leaves the factory.

Frequently Asked Questions

What is 2 methyl 5-nitroimidazole used for?

2-Methyl-5-nitroimidazole is a key intermediate in the synthesis of various nitroimidazole antibiotics and antiprotozoal agents. In veterinary medicine, it is formulated into suspensions for the treatment of anaerobic bacterial infections and protozoal diseases in livestock and companion animals. Its efficacy stems from the reduction of the nitro group within microbial cells, leading to the formation of toxic radicals that damage DNA.

Is nitroimidazole the same as metronidazole?

No, nitroimidazole is a class of compounds characterized by an imidazole ring with a nitro group substitution. Metronidazole is a specific drug within this class, namely 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole. While they share the core structure, metronidazole has an additional hydroxyethyl side chain that significantly alters its pharmacokinetic and pharmacodynamic properties. 2-Methyl-5-nitroimidazole is a precursor or degradation product of metronidazole, not the drug itself.

What is the difference between 4 Nitroimidazole and 5-nitroimidazole?

In the imidazole ring, the 4- and 5-positions are tautomerically equivalent when the nitrogen at position 1 is unsubstituted. Therefore, 4-nitroimidazole and 5-nitroimidazole refer to the same compound in such cases. However, when the 1-position is substituted (as in metronidazole), the nitro group is fixed at the 5-position. The numbering convention can cause confusion, but for 2-methyl-5-nitroimidazole (CAS 88054-22-2), the nitro group is unequivocally at the 5-position due to the methyl group at position 2.

What is the solubility of metronidazole?

Metronidazole has a solubility of approximately 10 mg/mL in water at 25°C, and it is sparingly soluble in alcohol. In contrast, 2-methyl-5-nitroimidazole has a lower aqueous solubility, typically around 5 mg/mL at 25°C, which poses challenges for suspension formulation. This limited solubility necessitates careful particle size control and the use of wetting agents to ensure uniform dispersion and bioavailability.

How can I prevent filter clogging when using non-ionic surfactants in my 2-methyl-5-nitroimidazole suspension?

Filter clogging is often due to crystal habit modification induced by surfactants like polysorbate 80. To prevent this, reduce surfactant concentration to 0.1–0.3%, add a polymeric stabilizer such as HPMC, and optimize wet milling to achieve a low crystal aspect ratio (≤3:1). Implement a two-stage filtration with 150-µm and 75-µm screens, and monitor pressure differentials. Pre-filter compatibility testing with your specific mesh size is essential.

What is the recommended filtration mesh size for micro-agglomerates in 2-methyl-5-nitroimidazole suspensions?

For typical veterinary suspensions with a target particle size D90 <20 µm, we recommend a final filtration through a 75-µm (200-mesh) screen. However, if needle-like crystals are present, even a 75-µm screen can blind. In such cases, use a 150-µm screen as a pre-filter and consider reformulating to reduce crystal aspect ratio. Always validate with your specific formulation and filling line.

How can I ensure color stability of my 2-methyl-5-nitroimidazole suspension under ambient light exposure?

2-Methyl-5-nitroimidazole is photolabile; exposure to UV and visible light can accelerate yellowing. Use amber glass or opaque HDPE bottles, and consider an aluminum foil overwrap. Formulation-wise, include a light-absorbing agent like titanium dioxide (if compatible) or an antioxidant system. In our stability studies, suspensions packaged in amber glass with nitrogen headspace showed minimal color change (<20 CU increase) over 12 months under ICH Q1B photostability conditions.

Sourcing and Technical Support

As a global manufacturer of high-purity 2-methyl-5-nitroimidazole, NINGBO INNO PHARMCHEM CO.,LTD. provides consistent quality with batch-specific COAs detailing critical parameters such as ORP, heavy metals, and particle size. Our product is a proven drop-in replacement for major brands, offering cost efficiency and reliable supply chain logistics, including IBC and 210L drum packaging. To request a batch-specific COA, SDS, or secure a bulk pricing quote, please contact our technical sales team.